Dr Daniel Felmlee
Profiles

Dr Daniel Felmlee

Lecturer in Hepatology

Peninsula Medical School (Faculty of Health)

Biography

Biography

Academic Lecturer in Hepatology

Qualifications

PhD Molecular Biology, University of Colorado Medical School

Thesis Title: Hepatitis C alters lipid and lipoprotein metabolism

Hepatits C virus (HCV) infection is a major health problem and the leading indication for liver transplantation in the US and Europe. HCV infection associates with disorders in lipid and lipoprotein metabolism including hepatic steatosis, an accumulation of fat in the liver. My previous work at University of Colorado School of Medicine, then University of California, San Diego focused on how HCV replication changes lipoprotein secretion from hepatoma cell lines, leading to lipid accumulation.

Following my interest in virus-host interactions of viral hepatitis, I pursued an MRC postdoc position in Newcastle upon Tyne investigating HCV virus/lipoprotein hybrid particles, lipoviral particles (LVP). I developed and collaboratively executed clinically based experiments that revealed LVPs to be dynamic transient particles dependent on host lipoprotein metabolism and external factors such as diet.

I then pursued and won a competitive fellowship from European Association for Study of the Liver (EASL) in Strasbourg, France. I used state-of-the-art molecular virology techniques using tissue culture models of HCV infection to further investigate functional relevance of lipoprotein and apolipoprotein interactions for viral entry and escape from host humoral defences. 

Professional membership

Editorial Board Member, World Journal of Hepatology
Reviewer, Journal of Infectious Diseases
Reviewer, Virology

Research

Research

Research interests

Primary Interest

Hepatitis C virus (HCV) infection is a major health problem with 3% of the global population infected. The natural history of HCV typically involves chronic infection resulting in hepatitis, fibrosis, cirrhosis, and end stage liver disease. A number of individuals who through risk factors or known exposure have been exposed to the virus, but neither have HCV RNA detectable in serum nor detectable anti-HCV antibodies. These exposed yet uninfected patients (EUs) appear to have either robust immune defences or other uncharacterized resistance to HCV infection. In the course of genome analysis of these individuals, we have identified candidate genes that are highly associated with HCV resistance. I seek to further characterize these genes through functional analysis using tissue culture HCV replication models.

Future studies will also focus on characterization of hepatitis B virus (HBV) in newly developed cell culture models and developing models of study for non-alcoholic fatty liver disease (NAFLD) and further inflammation signals that develop to non-alcoholic steatohepatitis (NASH).

Research groups

Publications

Publications

Key publications

Key publications are highlighted

Journals
Articles
Sheridan DA, Shawa IT, Thomas EL, Felmlee DJ, Bridge SH, Neely D, Cobbold JF, Holmes E, Bassendine MF & Taylor-Robinson SD (2022) 'Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis' Scientific Reports 12, (1) ,
Waris G, Felmlee DJ, Negro F & Siddiqui A (2020) 'Retraction for Waris et al., “Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress”' Journal of Virology 94, (19) ,
Felmlee DJ, Grün D & Baumert TF (2017) 'Zooming in on Liver Zonation' Hepatology 67, (2) 784-787 ,
Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME (2017) 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 ,
Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME (2017) 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis ,
Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ & Neely RD (2016) 'Hepatitis C virus and atherosclerosis: A legacy after virologic cure?' Clinics and Research in Hepatology and Gastroenterology 41, (1) 25-30 ,
Felmlee DJ & Baumert TF (2016) 'CD147 handles lipid: a new role for anti-cancer target' Translational Cancer Research 5, (3) 238-240 ,
Felmlee DJ, Coilly A, Chung RT, Samuel D & Baumert TF (2016) 'New perspectives for preventing hepatitis C virus liver graft infection' The Lancet Infectious Diseases 16, (6) 735-745 ,
Ahmed A & Felmlee D (2015) 'Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals' Viruses 7, (12) 6716-6729 ,
Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D & Abou-Jaoudé G (2015) 'A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses' Hepatology 63, (1) 35-48 ,
Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefèvre M, Magri A, Hiet M-S, Fofana I & Habersetzer F (2015) 'Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies' Gastroenterology 150, (1) 206-217.e4 ,
Bridge SH, Sheridan DA, Felmlee DJ, Crossey MME, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J & Thomas HC (2014) 'PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism' Journal of Hepatology 62, (4) 763-770 ,
Felmlee DJ, Schuster C & Baumert TF (2014) 'New tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology' Hepatology 60, (6) 1806-1808 ,
Lefèvre M, Felmlee DJ, Parnot M, Baumert TF & Schuster C (2014) 'Syndecan 4 Is Involved in Mediating HCV Entry through Interaction with Lipoviral Particle-Associated Apolipoprotein E' PLoS ONE 9, (4) 0-0 ,
Fauvelle C, Felmlee DJ & Baumert TF (2014) 'Unraveling hepatitis C virus structure' Cell Research 24, (4) 385-386 ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF (2014) 'Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency' Metabolic Brain Disease 29, (3) 625-634 ,
Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA & Urban S (2014) 'Entry of hepatitis B and C viruses — recent progress and future impact' Current Opinion in Virology 4, 58-65 ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick FI, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF (2013) 'Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial' Liver International 34, (5) 737-747 ,
Lupberger J, Duong FHT, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB & Heim MH (2013) 'Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha' Hepatology 58, (4) 1225-1235 ,
Felmlee DJ, Xiao F & Baumert TF (2013) 'Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture' Hepatology 58, (4) 1203-1206 ,
Felmlee DJ & Baumert TF (2013) 'Hepatitis C virus co-opts innate immunity component for lipid droplet formation' Journal of Hepatology 59, (5) 1118-1120 ,
Felmlee D, Hafirassou M, Lefevre M, Baumert T & Schuster C (2013) 'Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease' Viruses 5, (5) 1292-1324 ,
Lupberger J, Felmlee DJ & Baumert TF (2013) 'Interferon-lambda polymorphisms and hepatitis C virus clearance revisited' Hepatology 58, (1) 439-441 ,
Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF & Fafi-Kremer S (2013) 'Hepatitis C virus vaccines – Progress and perspectives' Microbial Pathogenesis 58, 66-72 ,
Zeisel MB, Felmlee DJ & Baumert TF (2013) 'Hepatitis C Virus Entry' 87-112 ,
Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ & Neely RDG (2012) 'Lipids and HCV' Seminars in Immunopathology 35, (1) 87-100 ,
Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F & Baumert TF (2012) 'Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection' Viruses 4, (10) 2016-2030 ,
Da Costa D, Turek M, Felmlee DJ, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB & Baumert TF (2012) 'Reconstitution of the Entire Hepatitis C Virus Life Cycle in Nonhepatic Cells' Journal of Virology 86, (21) 11919-11925 ,
Sheridan DA, Bridge SH, Felmlee DJ, Crossey MME, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RDG & Bassendine MF (2012) 'Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity' Journal of Hepatology 57, (1) 32-38 ,
Lupberger J, Felmlee DJ & Baumert TF (2012) 'Cholesterol uptake and hepatitis C virus entry' Journal of Hepatology 57, (1) 215-217 ,
Felmlee D, Sheridan D, Bridge S, Packard C, Caslake M, Toms G, Neely D & Bassendine M (2011) 'P44 Use of Intralipid infusion to analyse apolipoprotein B (apoB) and HCV RNA kinetics in chronic infection' Gut 60, (Suppl 2) A21-A21 ,
Bridge S, Sheridan D, Felmlee D, Crossey M, Thomas H, Taylor-Robinson S, Toms G, Neely D & Bassendine M (2011) 'P50 Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic hepatitis C infection: evidence for genotype-specific modulation of lipid pathways' Gut 60, (Suppl 2) A24-A24 ,
Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL & Neely RDG (2011) 'HCV and the hepatic lipid pathway as a potential treatment target' Journal of Hepatology 55, (6) 1428-1440 ,
Sheridan D, Bridge S, Felmlee D, Robinson ST, Thomas H, Toms G, Neely D & Bassendine M (2011) 'The 'interferon paradox' as a predictor of non-response to anti-viral therapy: novel association with apolipoprotein E and hepatitis C virus (HCV) lipoviralparticles (LVP)' Gut 60, (Suppl 1) A55-A56 ,
Sheridan P, Bridge S, Felmlee D, Taylor Robinson S, Thomas H, Toms G, Neely D & Bassendine M (2011) '1183 THE “INTERFERON PARADOX” AS A PREDICTOR OF NON-RESPONSE TO ANTI-VIRAL THERAPY: NOVEL ASSOCIATION WITH APOLIPOPROTEIN E AND HEPATITIS C VIRUS (HCV) LIPOVIRAL PARTICLES (LVP)' Journal of Hepatology 54, S467-S467 ,
Sheridan D, Crossey M, Thomas H, Taylor Robinson S, Felmlee D, Bridge S, Toms G, Neely D & Bassendine M (2011) '473 DEPRESSION IN CHRONIC HEPATITIS C IS ASSOCIATED WITH LOW APOLIPOPROTEIN E LEVELS' Journal of Hepatology 54, S193-S193 ,
Sheridan DA, Bartlett K, Felmlee DJ, Bridge SH, Toms GL, Dubuc G, Seidah NG, Davignon J, Neely RDG & Bassendine MF (2010) 'Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection – Reduced production or increased LDL clearance?' Atherosclerosis 213, (1) e4-e4 ,
Bridge SH, Sheridan DA, Felmlee DJ, Toms GL, Neely RDG & Bassendine MF (2010) 'Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection' Atherosclerosis 213, (1) e4-e4 ,
Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, Neely RDG, Toms GL & Bassendine MF (2010) 'Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection' Gut 60, (5) 680-687 ,
Sheridan D, Bridge S, Sheridan DA, Felmlee D, Thomas H, Taylor-Robinson S, Dermot R, Neely G, Toms GL & Bassendine MF (2010) 'OP14 Measurement of low density apolipoprotein B associated hepatitis C virus lipoviral particles in genotype 1 infection is more clinically relevant than total viral load' Gut 59, (Suppl 2) ,
Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL & Neely RDG (2010) 'Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles' Gastroenterology 139, (5) 1774-1783.e6 ,
Waris G, Felmlee DJ, Negro F & Siddiqui A (2007) 'Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress' Journal of Virology 81, (15) 8122-8130 ,
Domitrovich AM, Felmlee DJ & Siddiqui A (2005) 'Hepatitis C Virus Nonstructural Proteins Inhibit Apolipoprotein B100 Secretion' Journal of Biological Chemistry 280, (48) 39802-39808 ,
Conference Papers
Ahmed A, Dhanda A, Hegazy D, Felmlee D, Sheridan D & Cramp M (2016) 'Sustained viral clearance of HCV with DAA treatment is associated with restoration of effector T cell phenotype' 745A-745A
Mandalou P, Robinson MW, Felmlee D, Sieberhagen C, Mindos T, Hegazy D, MacLaughlan J & Cramp ME (2015) 'PTH-100 A comparative gene expression study between individuals with apparent resistance, spontaneous clearance, or chronic infection from hcv' BMJ A452.1-A452 ,
Felmlee DJ, Fauvelle C, Lefevre M, Heydmann L, Hiet M-S, Fofana I, Habersetzer F, Milne R, Patel AH & Vercauteren K (2014) 'Apolipoprotein E Functionally Obscures Hepatitis C Virus from Neutralizing Antibodies' 1064A-1064A
Verrier ER, Bach C, Heydmann L, Weiss A, Tawar RG, Felmlee D, Durand S, Durantel D, Zoulim F & Habersetzer F (2014) 'High-throughput hepatitis B and D virus model systems for discovery of targets for viral cure' 1038A-1038A
Lefevre M, Felmlee D, Baumert TF & Schuster C (2013) 'Syndecan 4 is the primary heparan sulfate proteoglycan mediating HCV entry through interaction with apolipoprotein E' 927A-927A
Turek M, Da Costa D, Felmlee D, Girardi E, Long G, Pfeffer S, Bartenschlager R, Zeisel MB & Baumert TF (2012) 'Reconstitution of the entire hepatitis C virus life cycle in a non-hepatic cell line' 704A-704A
Sheridan D, Crossey M, Robinson ST, Bridge S, Felmlee D, Thomas H, Toms G, Neely D & Bassendine M (2011) 'Depression in chronic hepatitis C is associated with low apolipoprotein e levels' BMJ A58-A58 ,
Bridge SH, Sheridan DA, Felmlee D, Thomas H, Crossey M, Taylor-Robinson SD, Toms GL, Neely D & Bassendine MF (2011) 'APOLIPOPROTEIN E AND LOW-DENSITY, APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN CHRONIC HEPATITIS C INFECTION: EVIDENCE FOR GENOTYPE-SPECIFIC MODULATION OF LIPID PATHWAYS' 1316A-1316A
Felmlee D, Sheridan DA, Bridge SH, Packard CJ, Caslake M, Toms GL, Neely D & Bassendine MF (2011) 'USE OF INTRALIPID INFUSION TO ANALYSE APOLIPOPROTEIN B (APOB) AND HCV RNA KINETICS IN CHRONIC INFECTION' 1320A-1320A
Sheridan D, Bridge S, Felmlee D, Robinson ST, Thomas H, Toms G, Neely D & Bassendine M (2011) 'THE "INTERFERON PARADOX" AS A PREDICTOR OF NON-RESPONSE TO ANTI-VIRAL THERAPY: NOVEL ASSOCIATION WITH APOLIPOPROTEIN E AND HEPATITIS C VIRUS (HCV) LIPOVIRAL PARTICLES (LVP)' S467-S467
Bridge SH, Sheridan DA, Felmlee D, Thomas H, Taylor-Robinson SD, Neely D, Toms GL & Bassendine MF (2010) 'MEASUREMENT OF LOW-DENSITY APOLIPOPROTEIN B ASSOCIATED LIPOVIRAL PARTICLES IN HEPATITIS C VIRUS GENOTYPE 1 INFECTION IS MORE CLINICALLY RELEVANT THAN TOTAL VIRAL LOAD' 435A-435A
Felmlee D, Sheridan DA, Bridge SH, Toms GL, Neely D & Bassendine MF (2010) 'THE HCV LIFE-CYCLE IN THE VASCULAR COMPARTMENT' 819A-820A
Bridge S, Sheridan DA, Felmlee D, Nielsen SU, Neely D, Toms GL & Bassendine MF (2009) 'APOLIPOPROTEIN B ASSOCIATED HEPATITIS C VIRUS (HCV): A MINORITY OF TOTAL VIRAL LOAD IN PATIENTS WITH CHRONIC HCV' 1061A-1061A
Felmlee D, Bridge S, Sheridan DA, Nielsen SU, Toms G, Neely D & Bassendine M (2009) 'LARGE AND BUOYANT HEPATITIS C VIRUS (HCV) PARTICLES SURGE AFTER PATIENTS CONSUME A HIGH-FAT MEAL' 314A-314A
Siddiqui A, Domitrovich A & Felmlee D (2006) 'Hepatitis C virus inhibits apolipoprotein B100 secretion' A1267-A1267
Presentations and posters
Sheridan DA, Gomez Romero M, Bridge S, Crossey M, Shawa IT, Neely D, Felmlee D, Holmes E, Bassendine M & Taylor-Robinson S Sheridan DA, Gomez Romero M, Bridge S, Crossey M, Shawa IT, Neely D, Felmlee D, Holmes E, Bassendine M & Taylor-Robinson S 'P0725 : Lipidomics analysis of fasting serum identifies novel lipid biomarkers specific for HCV genotype 3 and genotype 1 chronic hepatitis C virus infection' ,
Felmlee D, Redondo P, Ow M & Cramp M Felmlee D, Redondo P, Ow M & Cramp M 'Seeking genetic determinants of resistance to hepatitis C virus infection in a highly resistant cohort' ,
Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M 'Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort' ,
Felmlee DJ, Fauvelle C, Le Févre M, Heydmann L, Hiet M-S, Bartenschlager R, Fofana I, Habersetzer F, Milne R & Patel A Felmlee DJ, Fauvelle C, Le Févre M, Heydmann L, Hiet M-S, Bartenschlager R, Fofana I, Habersetzer F, Milne R & Patel A 'O52 APOLIPOPROTEIN E MEDIATES HCV ESCAPE FROM HOST NEUTRALIZING ANTIBODIES' ,
Felmlee DJ, Fauvelle C, Heydmann L, Hiet M-S, Fofana I, Bartenschlager R, Stoll-Keller F, Zeisel MB, Fafi-Kremer S & Baumert TF Felmlee DJ, Fauvelle C, Heydmann L, Hiet M-S, Fofana I, Bartenschlager R, Stoll-Keller F, Zeisel MB, Fafi-Kremer S & Baumert TF '1150 HEPATITIS C VIRUS LIVER TRANSPLANTATION ESCAPE VARIANT IS CHARACTERIZED BY BOTH ENHANCED TRIGLYCERIDE-RICH LIPOPROTEIN ASSOCIATION AND SENSITIVITY TO apoE ANTIBODIES' ,
Sheridan DA, Felmlee DJ, Bridge SH, Fenwick F, Askew B, Neely D, Crossey MME, Taylor-Robinson SD, Toms GL & Bassendine MF Sheridan DA, Felmlee DJ, Bridge SH, Fenwick F, Askew B, Neely D, Crossey MME, Taylor-Robinson SD, Toms GL & Bassendine MF '493 METABOLIC SYNDROME AND INSULIN RESISTANCE ARE ASSOCIATED WITH MAXIMUM HEPATITIS C LIPOVIRAL PARTICLES IN GENOTYPE 1 INFECTION' ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick F, Thomas HC, Neely D, Taylor-Robinson SD & Bassendine MF Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick F, Thomas HC, Neely D, Taylor-Robinson SD & Bassendine MF '903 OMEGA-3 FATTY ACIDS AND/OR FLUVASTATIN IN HEPATITIS C PRIOR NON-RESPONDERS TO COMBINATION ANTI-VIRAL THERAPY – A PILOT RANDOMISED CLINICAL TRIAL' ,
Sheridan D, Bartlett K, Felmlee D, Bridge SH, Toms GL, Dubuc G, Nabil S, Davignon J, Neely D & Bassendine MF Sheridan D, Bartlett K, Felmlee D, Bridge SH, Toms GL, Dubuc G, Nabil S, Davignon J, Neely D & Bassendine MF '1078 HYPOCHOLESTEROLAEMIA IN CHRONIC HEPATITIS C GENOTYPE 3 INFECTION IS DUE TO BOTH REDUCED CHOLESTEROL PRODUCTION AND INCREASED LDL CLEARANCE' ,
Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Neely RDG, Toms GL & Bassendine MF Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Neely RDG, Toms GL & Bassendine MF '1079 INSULIN RESISTANCE CORRELATES WITH LOW DENSITY HEPATITIS C VIRUS PARTICLES IN GENOTYPE 1 INFECTION' ,
Nielsen S, Sheridan D, Bridge S, Felmlee D, Neely D, Toms G & Bassendine M Nielsen S, Sheridan D, Bridge S, Felmlee D, Neely D, Toms G & Bassendine M '869 CHARACTERIZATION OF HEPATITIS C VIRUS PARTICLES IN HUMAN PLASMA: ASSOCIATION WITH IMMUNOGLOBULINS G1, G3 & M AND APOLIPOPROTEINS A-I, A-II, B, C-I AND E' ,